Verisante Technology, Inc. announced that it has received regulatory approval from the Federal Commission for Protection against Sanitary Risks (COFEPRIS), a division within the Mexican Ministry of Health, to market and sell Aura, a device for the detection of skin cancer, in Mexico. AuraTM is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information before making a final decision to biopsy. Basal cell and squamous cell skin cancers together make up about 96% of all skin cancers.

While early detection of melanoma is critical due to its high mortality rate, it is also important to detect the most common skin cancers early in order to achieve the best patient outcomes.